Literature DB >> 9846516

Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients.

D Wu1, D M Hockenberry, T A Brentnall, P H Baehr, R J Ponec, R Kuver, S P Tzung, J L Todaro, G B McDonald.   

Abstract

BACKGROUND: Persistent nausea, vomiting, anorexia, and poor oral intake are common after hematopoietic cell transplantation. In the past, herpesvirus infections and acute intestinal graft-versus-host disease (GVHD) were the most common causes.
METHODS: We studied 76 patients with 78 episodes of these symptoms to discern the causes. Diagnoses were based on histology of skin and intestinal biopsy specimens, viral cultures, and responses to therapy.
RESULTS: The mean day of study entry was day 57+/-31.3 posttransplant. Acute GVHD was the most common cause of symptoms, affecting 63 patients (81%) as the sole cause of symptoms and an additional 4 patients (5%) who had other concurrent causes. Patients with GVHD had marrow donors who were unrelated or HLA-mismatched in 27/63 cases. Gastric edema, erythema, and apoptotic epithelial cells were the most useful findings for the diagnosis of GVHD. Prednisone therapy (1-2 mg/kg/day) was effective in 58 of 63 patients (92%). Infection by herpes simplex virus, cytomegalovirus, or Candida was found in six patients, three of whom had concurrent GVHD. Other causes of symptoms were medications (one patients), parenteral nutrition (one patient), and sagittal sinus thrombosis (one patient).
CONCLUSIONS: Acute GVHD is now the dominant cause of persistent nausea and anorexia in marrow transplant patients who are beyond day 20 posttransplant. The diagnosis can be made clinically in most cases and confirmed by endoscopic biopsy of gastric mucosa. Infections, medications, and rare cases of central nervous system disease are much less common.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846516     DOI: 10.1097/00007890-199811270-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

1.  Prospective evaluation of acute graft-versus-host disease.

Authors:  Harry Aslanian; Bani Chander; Marie Robert; Dennis Cooper; Deborah Proctor; Stuart Seropian; Dhanpat Jain
Journal:  Dig Dis Sci       Date:  2011-10-20       Impact factor: 3.199

Review 2.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

3.  Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease.

Authors:  R S Mehta; Q Cao; S Holtan; M L MacMillan; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

4.  How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.

Authors:  George B McDonald
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

Review 5.  Viral infections of the gastrointestinal tract.

Authors:  R W Goodgame
Journal:  Curr Gastroenterol Rep       Date:  1999-08

6.  An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.

Authors:  Wendy M Leisenring; Paul J Martin; Effie W Petersdorf; Anne E Regan; Nada Aboulhosn; Jean M Stern; Saundra N Aker; Raymond C Salazar; George B McDonald
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

7.  Is single-cell apoptosis sufficient for the diagnosis of graft-versus-host disease in the colon?

Authors:  Christopher V Nguyen; David M Kastenberg; Cuckoo Choudhary; Leo C Katz; Anthony DiMarino; Juan P Palazzo
Journal:  Dig Dis Sci       Date:  2007-12-01       Impact factor: 3.199

Review 8.  The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease.

Authors:  Phuong L Doan; Nelson J Chao
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

9.  Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality.

Authors:  S Fuji; T Mori; N Khattry; J Cheng; Y R Do; K Yakushijin; S Kohashi; T Fukuda; S-W Kim
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483

10.  The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).

Authors:  Margaret F Bevans; Sandra A Mitchell; Susan Marden
Journal:  Support Care Cancer       Date:  2008-03-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.